mTOR, AMPK and Nutrient-Sensing Pathways in Aging

The idea in plain words

Cells keep track of food and energy with internal switches called nutrient-sensing pathways. Three come up most often in aging research. mTOR (mechanistic target of rapamycin) integrates signals such as growth factors and nutrition to direct cell growth, and helps control protein making and autophagy. [1] AMPK (AMP-activated protein kinase) has been described as an energy sensor involved in how cells respond to stress and in cellular aging. [2] Growth hormone and IGF-1 signaling is covered further down. A 2022 review describes how fasting, protein restriction and cutting specific amino acids change the activity of several of these pathways, including AKT, FOXO, mTOR, NAD+, AMPK and FGF21, in rodents and non-human primates, and says accumulating data suggest many of the same changes occur in humans. [3]

"Deregulated nutrient-sensing" is one of twelve proposed hallmarks of aging. [4] This page is education only. It gives no amounts, no diets and no advice about any medicine. Aging is not an approved medical indication for any drug mentioned.

mTOR: strong animal evidence, thin human evidence

• Mice: a 2009 study gave rapamycin, a drug that blocks mTOR, to genetically varied mice starting late in life. It extended median and maximum lifespan at three test sites; at the age when 90% had died, the gain was 14% in females and 9% in males. [5] Label: preclinical.
• Older adults and vaccines: in a 2014 trial in elderly volunteers, an mTOR inhibitor related to rapamycin improved the response to flu vaccine by about 20% at doses that were relatively well tolerated, and lowered the share of T cells carrying a marker called PD-1. [6] The study measured vaccine response, not infections or survival. Label: promising but limited.
• Healthy adults: the 48-week PEARL trial randomized healthy adults to weekly low-dose rapamycin or placebo. Adverse events were similar across groups, and the main outcome, belly fat, did not change significantly. Lean mass and self-reported pain improved in women in one dose group, and some self-reported well-being scores improved in the other. The authors disclose being employees and shareholders of a company named in the paper. [7] Label: insufficient evidence of benefit; early safety data only.
• Muscle: a 2026 review reports that trials of metformin and once-weekly sirolimus did not improve their planned functional outcomes in the groups and regimens tested. [8]
• Broader reviews: a 2026 systematic review found that mTOR-targeting interventions had effects on selected tissue and immune outcomes, but small samples and short follow-up limit conclusions. [9]

Regulatory status. Sirolimus, also known as rapamycin, is an mTOR inhibitor used as an immunosuppressant. [10] Its US label lists preventing organ rejection in kidney transplant patients and treating lymphangioleiomyomatosis, and carries a boxed warning that immunosuppression raises susceptibility to infection and possible lymphoma. [10] Aging is not a labeled use, and this page is not guidance to take it. Rapamycin and the related research are covered in rapamycin and mTOR inhibitors in aging research.

AMPK and the metformin question

A 2026 review of intermittent fasting lists AMPK, mTOR and related proteins among the nutrient-sensing pathways that fasting modulates. [11] In muscle, a 2025 review describes AMPK/SIRT1/PGC-1 alpha signaling and mTORC1 as regulators of mitochondrial production, protein building and quality control. [12] Metformin is often discussed in this context. Its US label lists a single use, to improve blood sugar control in adults and children 10 and older with type 2 diabetes. [13] It is not approved for aging. See metformin and aging research.

Growth hormone and IGF-1

Mice with genetic growth hormone deficiency or resistance live longer than normal siblings. [14] In people, a group in Ecuador with growth hormone receptor deficiency (Laron syndrome) and a group in Brazil with a growth hormone-releasing hormone receptor defect have been studied. The Brazil group are described as partly protected from cancer and some common effects of aging, and one person reached 103. [14] Adults with the Ecuador condition had lower glucose, insulin and blood pressure than relatives, but the study was small (21 affected people) and those outcomes are risk factors, not lifespan. [15] These are rare genetic conditions, not a basis for lowering growth hormone on purpose. Label: preclinical for lifespan, insufficient evidence for any intervention. See growth hormone and IGF-1 signaling.

Calorie restriction in people

The CALERIE trial randomized 220 adults without obesity to 25% calorie restriction or usual eating for 2 years. One DNA-based pace-of-aging measure slowed slightly, other biological-age clocks did not change significantly, effects were small, and the authors say conclusive testing needs long-term follow-up on disease and death. [16] Label: promising but limited (biomarker). Compare approaches in calorie restriction and aging research.

How to evaluate a pathway claim

1. "Activates AMPK" or "inhibits mTOR" describes a switch, not a health outcome.
2. Ask whether lifespan or disease was measured in people, or only in mice or cells.
3. Be wary of claims that blocking growth signals is risk-free. The US label of one mTOR-blocking drug carries a boxed warning about infection and lymphoma. [10]